abstract BACKGROUND: After reports of increasing emergency department (ED) visits for unsupervised pediatric medication exposures in the 2000s, renewed efforts to improve safety packaging and education were initiated. National data on current trends can help further target interventions.
WHAT'S KNOWN ON THIS SUBJECT:
Unsupervised medication exposures increased during the previous decade, despite child-resistant packaging and caregiver education. To achieve the Healthy People 2020 objective of reducing emergency department visits for unintentional pediatric medication overdoses, targeted interventions including improved safety packaging may be needed.
WHAT THIS STUDY ADDS:
Since 2010, emergency department visits for unsupervised medication exposures started to decrease. Most visits involved solid dose medications, typically for adult use. Most liquid medication exposure visits involved 4 over-the-counter pediatric products and may be more readily amenable for interventions. Unsupervised medication exposures remain a significant but preventable cause of pediatric harm. For decades, the cornerstones of primary prevention have been child-resistant (CR) packaging (required for most medications in the United States) 1 and education regarding safe medication storage. Despite great success in reducing the numbers of pediatric poisoning deaths, 2 each year ∼500 000 calls are made to poison centers after a young child accesses medication without adult supervision, [3] [4] [5] and from 2001 through 2008, the number of pediatric exposure calls that resulted in emergency department (ED) evaluation increased 24% to 32% depending on medication type. 6 Since then, renewed efforts have been made to improve child safety packaging and education, 7, 8 and reducing ED visits for unintentional medication overdoses among young children was adopted as a Healthy People 2020 goal for the nation. 9 Nationally representative surveillance data were used to assess trends in ED visits for unsupervised medication exposures among children aged , 6 years from 2004 through 2013. To help target prevention efforts, the medications implicated in ED visits from 2010 through 2013 were characterized according to dosage form and prescription status, and those most commonly implicated were identified.
METHODS

Data Sources
National estimates of ED visits for unsupervised pediatric medication exposures were based on data from the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance (NEISS-CADES) project. Initiated in 2004, NEISS-CADES is an active public health surveillance system based on a nationally representative sample of hospitals with at least 6 beds and a 24-hour ED in the United States and its territories; the project has been described elsewhere in detail. 10 For this analysis, medications available only by prescription were categorized as prescription. Medications available either by prescription or OTC were categorized based on case details such as brand name or dosage strength (eg, "ibuprofen 800-mg tablets"); in the absence of clarifying details, they were categorized as available OTC. Medications available only OTC were categorized as OTC. OTC medications were further categorized as pediatric products, adult/family products, or unspecified age group products based on the product name, dosage form, or narrative details (eg, "children's acetaminophen"). Medications described generally (eg, "eye drops," "white pill") were categorized as unspecified prescription status.
For ED visits without specific documentation of pediatric selfadministration, caregiver administration was assumed. These included adverse reactions, allergic reactions, supratherapeutic effects, medication errors, and secondary effects (eg, choking).
Statistical Analysis
NEISS-CADES cases are weighted based on the inverse probability of selection, adjusted for nonresponse and poststratified to adjust for the number of annual hospital ED visits. 14 National estimates of ED visits and corresponding 95% confidence intervals (CIs) were calculated by using the SURVEYMEANS procedure in SAS version 9.3 (SAS Institute, Inc, Cary, NC) to account for weighting and complex sample design. Population-based rates were calculated by using intercensal estimates from the US Census Bureau. Most ED visits for ADEs were attributed to unsupervised exposures during the first part of the study period. However, joinpoint regression identified a significant decline in the proportion of visits attributed to 21 and are currently implemented on infants' and some children's singleingredient acetaminophen products. 22 A new final guidance from the US Food and Drug Administration recommends expanding use of such container features to prevent or limit pediatric exposures to all OTC pediatric liquid acetaminophen-containing products. 23 Although approximately one-half of ED visits for medication exposures involved prescription solid medications, the targeting of interventions is more complex because these exposures involve a broader range of products, typically intended for adults, which are often repackaged at retail pharmacies and are more easily transferred out of CR containers in the home. Although only 1 pediatric medication (ie, singleingredient acetaminophen) was implicated in one-third of ED visits for OTC liquid exposures from 2010 through 2013, ten medications combined accounted for one-third of visits for prescription solid exposures.
NEISS-CADES estimates based on
With so many different implicated 29, 30 Fourth, although medication utilization was not assessed, future studies could identify specific medications with disproportionate rates of unsupervised exposure relative to use, and assess medication-specific trends.
CONCLUSIONS
The observed decline in estimated ED visits for unsupervised exposure cannot be attributed to specific interventions; however, the decline coincides with renewed prevention efforts, including those of the PRevention of Overdoses and Treatment Errors in Children Taskforce (PROTECT) Initiative and its partners. 8, 22, [31] [32] [33] [34] 
